Xenetic Biosciences (NASDAQ:XBIO) Shares Up 6.1% – Here’s What Happened

Shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) were up 6.1% on Friday . The company traded as high as $2.49 and last traded at $2.42. Approximately 80,930 shares traded hands during trading, an increase of 307% from the average daily volume of 19,887 shares. The stock had previously closed at $2.28.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Xenetic Biosciences has an average rating of “Reduce”.

Xenetic Biosciences Stock Up 6.1%

The firm has a market cap of $5.54 million, a PE ratio of -1.18 and a beta of 2.25. The stock’s fifty day simple moving average is $2.35 and its two-hundred day simple moving average is $3.13.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.16. The firm had revenue of $1.03 million during the quarter. Xenetic Biosciences had a negative net margin of 110.42% and a negative return on equity of 64.66%. On average, equities research analysts anticipate that Xenetic Biosciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC raised its stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,259 shares of the company’s stock after acquiring an additional 4,593 shares during the period. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 as of its most recent SEC filing. 15.12% of the stock is currently owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.